Kura Oncology (NASDAQ:KURA) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
A number of other research analysts have also weighed in on the company. Oppenheimer set a $18.00 target price on Kura Oncology and gave the company a “buy” rating in a report on Thursday, November 16th. Citigroup lifted their price target on Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. Cann reiterated a “buy” rating on shares of Kura Oncology in a research report on Wednesday, November 8th. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, Cowen started coverage on Kura Oncology in a research report on Thursday, September 7th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $17.60.
Shares of Kura Oncology (KURA) traded down $0.70 on Friday, reaching $15.35. The company had a trading volume of 192,231 shares, compared to its average volume of 251,060. Kura Oncology has a 52 week low of $4.95 and a 52 week high of $17.50. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07.
A number of large investors have recently added to or reduced their stakes in the stock. Iguana Healthcare Management LLC bought a new stake in Kura Oncology in the 3rd quarter worth approximately $1,346,000. California State Teachers Retirement System lifted its position in Kura Oncology by 24.5% in the third quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock valued at $471,000 after purchasing an additional 6,200 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Kura Oncology by 61.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after buying an additional 14,900 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $802,000. Finally, EAM Investors LLC purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $2,884,000. Institutional investors own 64.26% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Kura Oncology (KURA) Stock Rating Lowered by ValuEngine” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/03/kura-oncology-kura-stock-rating-lowered-by-valuengine.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
What are top analysts saying about Kura Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kura Oncology Inc. and related companies.